Interleukin- 10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice

Molecular Medicine

Volumn 9, Issue 1-2, 2003, Pages 10-17

  Caligiuri, Giuseppina ^a   Rudling, Mats ^c   Ollivier, Véronique ^a   Jacob, Marie Paule ^a   Michel, Jean Baptiste ^a   Hansson, Göran K ^b   Nicoletti, Antonino ^a  

^a INSERM   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; GELATINASE A; GELATINASE B; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; PROCOAGULANT; THROMBIN; THROMBOPLASTIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HELPER CELL; KNOCKOUT MOUSE; LIPOPROTEIN METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN FUNCTION; THROMBOSIS;

EID: 0038544576     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402102     Document Type: Article

References (52)

1. Hansson GK. (2001) Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:1876-90.
2. Mallat Z et al. (1999) Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85:e17-24.
3. Pinderski LJ et al. (2002) Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90:1064-71.
4. Pinderski Oslund LJ et al. (1999) Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19:2847-53.
5. Laurat E et al. (2001) In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104:197-202.
6. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. (2002) Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109:745-53.
7. Seder RA, Gazzinelli R, Sher A, Paul WE. (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. U.S.A. 90:10188-92.
8. Mosmann TR, Coffman RL. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-73.
9. Liblau RS, Singer SM, McDevitt HO. (1995) Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16:34-8.
10. Mallat Z et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler. Thromb. Vasc. Biol. 19:611-6.
11. Uyemura K et al. (1996) Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 97:2130-8.
12. Honsson GK, Holm J, Jonasson L. (1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135:169-75.
13. Zhou X, Paulsson G, Stemme S, Honsson GK. (1998) Hypercholesterolemia is associoted with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101:1717-25.
14. Lee TS, Yen HC, Pan CC, Chau LY. (1999) The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:734-42.
15. Gupta S et al. (1997) IFN-γ potentiates otherosclerosis in ApoE knockout mice. J. Clin. Invest. 99:2752-61.
16. -/- mice. Am. J. Pathol. 157:1819-24.
17. Liuzzo G et al. (2000) Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 101:2883-8.
18. Hansson GK, Hellstrand M, Rymo L, Rubbia L, Gabbiani G. (1989) Interferon γ inhibits both proliferation and expression of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170:1595-608.
19. Amento EP, Ehsani N, Palmer H, Libby P. (1991) Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscl. Thromb. 11:1223-30.
20. Libby P. (1995) Molecular bases of the acute coronary syndromes. Circulation. 91:2844-50.
21. Saren P, Welgus HG, Kovanen PT. (1996) TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 157:4159-65.
22. Amman V, Stemme S, Rymo L, Risberg B. (1995) Interferon-γ modulates the fibrinolytic response in cultured human endothelial cells. Thromb. Res. 77:431-40.
23. Gallicchio M, Hufnagl P, Wojta J, Tipping P. (1996) IFN-γ inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J. Immunol. 157:2610-7.
24. Stearns ME, Rhim J, Wang M. (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin. Cancer Res. 5:189-96.
25. Ramani M et al. (1993) Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes. FEBS Lett. 334:114-6.
26. Pajkrf D et al. (1997) Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood. 89:2701-5.
27. Furukawa Y, Becker G, Stinn JL, Shimizu K, Libby P, Mitchell RN. (1999) Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of IL-10 in vivo. Am. J. Pathol. 155:1929-39.
28. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. (1998) Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102:910-8.
29. Gullberg H, Rudling M, Forrest D, Angelin B, Vennstrom B. (2000) Thyroid hormone receptor β-deficient mice show complete loss of the normal cholesterol 7α-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. Mol. Endocrinol. 14:1739-49.
30. Openshaw P et al. (1995) Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J. Exp. Med. 182:1357-67.
31. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 75:263-74.
32. Biasucci LM et al. (1996) Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation. 93:2121-7.
33. -/- mice. FASEB J. 15:2730-2.
34. Caligiuri G, Nicoletti A, Zhou X, Tomberg I, Hansson GK. (1999) Effects of sex and age on atherosclerosis and autoimmunity in apoE deficient mice. Atherosclerosis. 145:301-8.
35. -/- mice. J. Interferon Cytokine Res. 22:661-70.
36. Carlsten H, Tarkowski A, Holmdahl R, Nilsson LA. (1990) Oestrogen is a potent disease accelerator in SLE-prone MRL Ipr/Ipr mice. Clin. Exp. Immunol. 80:467-73.
37. Carlsten H, Nilsson N, Jonsson R, Tarkowski A. (1991) Differential effects of oestrogen in murine lupus: acceleration of glomerulonephritis and amelioration of T cell-mediated lesions. J. Autoimmun. 4:845-56.
38. Carlsten H et al. (1992) Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL Ipr/Ipr mice. Cell. Immunol. 144:190-202.
39. Carlsten H, Tarkowski A. (1993) Histocompatibility complex gene products and exposure to oestrogen: two independent disease accelerating factors in murine lupus. Scand. J. Immunol. 38:341-7.
40. Holmdahl R, Carlsten H, Jansson L, Larsson P. (1989) Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. Br. J. Rheumatol. 28:54-8.
41. Verthelyi D, Klinman DM. (2000) Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 100:384-90.
42. Tracey KJ, Cerami A. (1990) Metabolic responses to cachectin/TNF. A brief review. Ann. N.Y. Acad. Sci. 587:325-31.
43. Packard CJ, Shepherd J. (1997) Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17:3542-56.
44. Veniant MM, Withycombe S, Young SG. (2001) Lipoprotein size and atherosclerosis susceptibility in ApoE(-/-) and LDLR(-/-) mice. Arterioscler. Thromb. Vasc. Biol. 21:1567-70.
45. Jonsson SW et al. (2001) Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J. Rheumatol. 28:2597-602.
46. Hurt-Camejo E et al. (2001) Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 44:2761-7.
47. Ardissino D et al. (1997) Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 349:769-71.
48. Kai H et al. (1998) Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32:368-72.
49. Johnson JL, Jackson CL. (2001) Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis. 154:399-406.
50. Rosenfeld ME et al. (2000) Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 20:2587-92.
51. Merlini PA et al. (1995) Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 15:1675-9.
52. Downing LJ et al. (1998) IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J Immunol. 161:1471-6.